OVID
insider transactionsOvid Therapeutics Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-20.2K
0 buy · 20.2K sell
Net value · 365d
-$29.3K
$0 in · $29.3K out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
2
0 buy · 20.2K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Grant·A
Director
$0
130.0K sh
Own New
-
Grant·A
Director
$45.0K
17.6K sh · $2.56
Own +9%
-
Grant·A
Director
$22.5K
8.8K sh · $2.56
Own New
-
Grant·A
Director
$45.0K
17.6K sh · $2.56
Own New
-
Exercise·M
Jeremy M Levin KEY
Executive Chairman
$0
47.3K sh
Own New
-
Exercise·M
Jeremy M Levin KEY
Executive Chairman
$66.3K
47.3K sh · $1.40
Own +1%
-
Grant·A
CBFO
$0
408.8K sh
Own New
-
Grant·A
CBFO
$0
68.1K sh
Own +77%
-
Grant·A
Director
$0
65.0K sh
Own New
-
Grant·A
Director
$0
957.0K sh
Own New
-
Grant·A
Director
$0
65.0K sh
Own New
-
Grant·A
Director
$0
65.0K sh
Own New
-
Grant·A
Director
$0
65.0K sh
Own New
-
Grant·A
President and CEO
$0
1.4M sh
Own New
-
Sell·S
CBFO
$12.4K
8.5K sh · $1.45
Own -9%
-
Sell·S
President and CEO
$16.9K
11.7K sh · $1.45
Own -16%
-
Grant·A
President and CEO
$0
890.0K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Jun 15, 2026 | Anna Greka | Grant A | 130.0K | $0 |
| Apr 7, 2026 | Stelios Papadopoulos | Grant A | 17.6K | $45.0K |
| Apr 7, 2026 | Bart Friedman | Grant A | 8.8K | $22.5K |
| Apr 7, 2026 | Kevin Joseph Fitzgerald | Grant A | 17.6K | $45.0K |
| Mar 23, 2026 | Jeremy M Levin KEY | Exercise M | 47.3K | $0 |
| Mar 23, 2026 | Jeremy M Levin KEY | Exercise M | 47.3K | $66.3K |
| Feb 26, 2026 | Jeffrey A Rona | Grant A | 408.8K | $0 |
| Feb 26, 2026 | Jeffrey A Rona | Grant A | 68.1K | $0 |
| Feb 26, 2026 | Stelios Papadopoulos | Grant A | 65.0K | $0 |
| Feb 26, 2026 | Jeremy M Levin | Grant A | 957.0K | $0 |
| Feb 26, 2026 | Bart Friedman | Grant A | 65.0K | $0 |
| Feb 26, 2026 | Kevin Joseph Fitzgerald | Grant A | 65.0K | $0 |
| Feb 26, 2026 | Karen Bernstein | Grant A | 65.0K | $0 |
| Feb 26, 2026 | Margaret A. Alexander KEY | Grant A | 1.4M | $0 |
| Feb 23, 2026 | Jeffrey A Rona | Sell S | 8.5K | $12.4K |
| Feb 23, 2026 | Margaret A. Alexander KEY | Sell S | 11.7K | $16.9K |
| Jan 4, 2026 | Margaret A. Alexander KEY | Grant A | 890.0K | $0 |
About OVID insider trading
This page tracks insider transactions for Ovid Therapeutics Inc. (OVID) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.